echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > WHO passed 6 guidelines including data integrity and pharmaceutical water GMP

    WHO passed 6 guidelines including data integrity and pharmaceutical water GMP

    • Last Update: 2021-07-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, the WHO Expert Committee on Pharmaceutical Standards (ECSPP) released its 55th technical report
    .
    In October 2020, ECSPP held its 55th annual meeting in the form of a virtual meeting.
    This report is a summary of relevant discussions and follow-up work of the meeting

    .


    Through a series of guides

    ECSPP is one of the earliest committees established by WHO.
    The scope of ECSPP's work has also been continuously expanded.
    It involves GMP, technical guidance documents for drug management, quality control laboratory quality management (GPCL), and counterfeit and substandard drugs.
    Processing and other links

    .
    ECSPP has also formulated a large number of special guidelines related to GMP and quality systems.
    In this technical report, ECSPP has adopted a series of guidelines in this regard, including:

    • Points to consider when including Health Based Exposure Limits (HBELs) in cleaning validation;

    • GMP (Good manufacturing practices: water for pharmaceutical use)

    • Guideline on data integrity;

    • WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce (WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce);

    • Good reliance practices in the regulation of medical products: high-level principles and considerations;

    • Good regulatory practices in the regulations of medical products
      .

    Data Integrity Guidelines

    Among the guidelines adopted above, the data integrity guidelines have been significantly updated compared to the previous version
    .
    This guidance replaces the 2016 “WHO Guidance on good data and record management practices” (WHO Guidance on good data and record management practices).
    The main reason is that the 2016 guidance was considered too lengthy, and many other institutions have recently expressed interest in this topic.
    Made adjustments

    .
    The new guidelines will better reflect current expectations and focus on necessary information

    .

    The content of the new guidelines is as follows.
    The requirements for data integrity are described in 10 main areas (Parts 4-10).
    The appendix contains 10 examples of data integrity management, from quality risk management to data entry, change and control.

    .



    1.
    Introduction and background


    2.
    Scope


    3.
    Glossary


    4.
    Data governance


    5.
    Quality risk management


    6.
    Management review


    7.
    Outsourcing


    8.
    Training


    9.
    Data, data transfer and data processing (Data, data transfer and data processing)


    10.
    Good documentation practices


    11.
    Computerized systems


    12.
    Data review and approval


    13.
    Corrective and preventive actions (Corrective and preventive actions)


    Appendix 1: Examples in data integrity management Appendix 1: Examples in data integrity management




    Between November 2019 and January 2020, the first draft of the new guidelines was open for comments.
    This version and the more than 440 comments received were discussed at the virtual inspector meeting in June 2020

    .
    Since then, the draft guidelines have been revised and public comments have been requested again

    .
    During the second comment period, the WHO Secretariat received approximately 650 comments.
    The suggestions included:

    • Reorganize the content of the "Introduction" section;

    • Add information about "Data Governance", "Data Transmission" and "Computerized Systems";

    • Expand the content of the "Quality Risk Management Control" section;

    • Clarify the management review system and actions in case of non-compliance;

    • Add a new section "Data Review and Approval";

    • Improve some examples and make some editorial revisions
      .

    The guidance document was revised accordingly in accordance with the above recommendations and submitted to ECSPP
    .
    ECSPP then reviewed the latest amendments and discussed related issues, including compliance with data protection regulations and best times, data retention schedules, and data transmission requirements

    .
    In addition, ECSPP also discussed the scope of the document, such as the value of covering relevant content: vector control products, safety and efficacy data generated in clinical research under good clinical practice

    .
    Therefore, ECSPP members proposed new wording for the scope of application and suggested adding the term "medical products" to the glossary

    .
    In general, the committee of experts expressed strong support for the new data integrity guidelines and pointed out that the guidelines are comprehensive and greatly improved

    .
    ECSPP members agreed that the new guidelines will be of great value to the industry and inspectors

    .

    Ref.
    : TRS 1033-55th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations.
    WHO Technical Report Series 1033.
    25 March 2021.

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.